Semaglutide in Early Type 1 Diabetes

This retrospective analysis evaluated the effects of semaglutide in 10 patients with new onset type 1 diabetes. Initiated within 3 months of diagnosis, semaglutide (up to 0.5 mg weekly) allowed discontinuation of prandial insulin in all patients and basal insulin in 7 patients by 6 months. At 12 months, mean glycated hemoglobin improved from 11.7% to 5.7%, fasting C peptide levels increased (0.65 to 1.05 ng/mL), and time in range glucose was 89%. No severe hypoglycemia or ketoacidosis occurred. Compared to historical controls, semaglutide appeared to prolong the "honeymoon period" of preserved beta cell function. The findings suggest potential benefits of GLP 1 agonists in early type 1 diabetes, warranting prospective trials.

This retrospective analysis evaluated the effects of semaglutide in 10 patients with new onset type 1 diabetes. Initiated within 3 months of diagnosis, semaglutide (up to 0.5 mg weekly) allowed discontinuation of prandial insulin in all patients and basal insulin in 7 patients by 6 months. At 12 months, mean glycated hemoglobin improved from 11.7% to 5.7%, fasting C peptide levels increased (0.65 to 1.05 ng/mL), and time in range glucose was 89%. No severe hypoglycemia or ketoacidosis occurred. Compared to historical controls, semaglutide appeared to prolong the "honeymoon period" of preserved beta cell function. The findings suggest potential benefits of GLP 1 agonists in early type 1 diabetes, warranting prospective trials.